Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

OBJECTIVES/HYPOTHESIS: Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)‐4/IL‐13 receptor component, significantly improved outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the SINUS‐24 and SINUS‐52 studies. This post hoc analysis eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Chien‐Chia, Guillemin, Isabelle, Bachert, Claus, Lee, Stella E., Hellings, Peter W., Fokkens, Wytske J., Duverger, Nicolas, Fan, Chunpeng, Daizadeh, Nadia, Amin, Nikhil, Mannent, Leda P., Khan, Asif H., Kamat, Siddhesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Allergy, Rhinology, and Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299704/
https://www.ncbi.nlm.nih.gov/pubmed/34817082
http://dx.doi.org/10.1002/lary.29911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299704/
https://www.ncbi.nlm.nih.gov/pubmed/34817082
http://dx.doi.org/10.1002/lary.29911

Ejemplares similares